Overview
Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination
Criteria
Inclusion Criteria:- Patients with documented heart failure (NYHA class II-IV)
Exclusion Criteria:
- Use of both ACEi and ARB, ACEi and DRI, ARB and DRI treatment, or all three
medications at Screening